Catheter Precision (NYSE American: $VTAK ) Poised for European Expansion Gaining Momentum
Investors are consistently seeking companies at the forefront of innovative solutions, and one such entity worth exploring is Catheter Precision (NYSE American: VTAK). This U.S.-based medical device company focuses on advancing cardiac arrhythmia treatment by introducing novel solutions to the market.
Catheter Precision is dedicated to developing groundbreaking technology for electrophysiology procedures, aiming to enhance these processes through ongoing collaboration with physicians and continuous product refinement. Formerly known as Ra Medical Systems Inc., the company officially changed its name to Catheter Precision on August 17, 2023.
The company’s recent surge in stock momentum is attributed to its potential expansion into Europe. On November 20, Catheter Precision made headlines by successfully completing its initial VIVO cases in the southeastern region of Europe. VIVO, the company’s non-invasive 3D imaging system, is employed before procedures to pinpoint ventricular ablation points of interest. It plays a crucial role in pre-procedural planning, enhancing procedural accuracy, and providing essential support to physicians.
The evaluation of the VIVO system took place during four ventricular ablation procedures at Dubrava University Hospital in Zagreb, Croatia. Dr. Ivan Zalikovic, Head of the Electrophysiology Lab at Dubrava University Hospital, expressed satisfaction with VIVO’s simplicity and flexibility in workflow. He commended the system for surpassing expectations, particularly highlighting the impressive maps it generated.